Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neogen Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit. The focus on this technology area highlights the company's current intellectual property activities and its commitment to innovation in this field.
ARIANI, KADE is the busiest examiner for the portfolio, with 1 pending office action. This single action represents the total of 1 pending office action for the company. The prosecution is currently limited to a single examiner and a single art unit, which streamlines the administrative process for the applicant.
Because there is only 1 distinct examiner involved, the company's strategy for its 1 pending office action is centered on the review by ARIANI, KADE. The presence of 1 distinct art unit indicates a specific regulatory path within the Biotechnology & Pharmaceuticals sector. This focused approach allows the company to concentrate its resources on a single point of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 74.9% | +32.4% |
| SCHMIDT, EMILY LOUISE | 1 | 58.4% | +36.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695069 | Sample Preparation and Detection Methods Using Enzymatic Digestion | ARIANI, KADE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695069 | Sample Preparation and Detection Methods Using Enzymatic Digestion | ARIANI, KADE | — |
| 17968327 | Hypodermic Interface Assembly | SCHMIDT, EMILY LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695069 | Sample Preparation and Detection Methods Using Enzymatic Digestion | ARIANI, KADE | 1651 | §102§103 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 17968327 | Hypodermic Interface Assembly | SCHMIDT, EMILY LOUISE | 3783 | §103 | Non-Final OA | — | Pending | Oct 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial